Drug intelligence / Profile preview

99mTc-EC + amifostine

Development stage: Preclinical
Lead developer: Cell>Point LLC
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**99mTc-EC + amifostine** is an investigational **radiopharmaceutical theranostic** being developed by **Cell>Point**. It combines **technetium-99m** with **EC-amifostine**, a modified amifostine construct designed to interact with **alkaline phosphatase** biology. Based on the provided context, EC-amifostine is metabolized by alkaline phosphatase to a thiol analog that scavenges free radicals and stabilizes DNA, while the technetium-99m label enables diagnostic imaging. The program has been described for imaging applications including differentiation of tumor progression from viral infection-related involvement and for monitoring therapeutic response in **COVID-19**, positioning it as a small-molecule-based radiotheranostic/imaging agent rather than a conventional systemic therapeutic.

Other names: 99mTc-EC-AmifostineEC-Amifostinetechnetium-99m EC-amifostinetechnetium99m EC-amifostinetechnetium 99m EC-amifostine

Targets

DNAALPL (Tissue-nonspecific alkaline phosphatase)

Beyond the preview

Go deeper on 99mTc-EC + amifostine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-EC + amifostine.

Explore the full profile